Two studies recently released show a survival benefit for intraperitoneal IP chemotherapy
Related Topics

Researchers Discover Potential Therapeutic Targets for Low-Grade Serous Ovarian Cancer
Scientists have identified sixteen potential therapeutic targets in low-grade serous ovarian cancer by studying proteins at the molecular level, with results published on August 11, 2025, in the journal Cancer … Continued

OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued

FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued